At a glance
ClinicalIndex Comparison RecordN/ACompleted· 101 enrolled
Drug / intervention
Hemodynamic management using CardioMEMS HF Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation to Optimize Hemodynamic Management of HeartMate II™ Left Ventricular Assist Device Patients Using the CardioMEMS™ Pulmonary Artery Pressure Sensor in Advanced Heart Failure
In Brief
An observational study evaluating Hemodynamic management using CardioMEMS HF System for Heart Failure. Completed, enrolled 101 participants across 23 sites.
Detailed Summary
This observational post market study is intended to characterize hemodynamic-guided management of patients with an existing left ventricular assist device (LVAD) to protocol specified target ranges and its impact on functional status, quality of life, and readmissions
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionMar 2020
Study CompletionJun 2020
TodayJul 2026
First PostedAug 14, 2017
Enrollment StartAug 24, 2017
Primary CompletionMar 6, 2020
Study CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.9 years ago
Interventions
Hemodynamic management using CardioMEMS HF Systemdevice
Using the CardioMEMS HF System, clinicians will treat to target PA pressure ranges